Compare Adaptive Biotechnologies Corp (ADPT) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Financial Select Sector SPDR Fund — how do they compare? Adaptive Biotechnologies Corp trades at $25.17 (market cap $4.04B), while Financial Select Sector SPDR Fund trades at $57.74. Which is the better fit depends on your goals.
| ADPT | XLF | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $58.01 |
52-Week Low | $12.30 | $47.80 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
XLF trades at $57.88, up 0.12% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF recently crossed above its 200-day moving average, indicating positive momentum. Recent news highlights strong inflows into sector ETFs and potential opportunities from AI infrastructure financing.
The outlook for XLF is supported by technical strength and sector tailwinds, but overbought RSI levels suggest near-term caution. Key risks include interest rate sensitivity and market volatility. Analyst sentiment is generally positive, focusing on the financial sector's role in economic growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
